- Home
- FICO vs TAK Comparison
FICO vs TAK Comparison
Compare FICO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FICO | TAK |
|---|---|---|
| Founded | 1956 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 43.3B |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | FICO | TAK |
|---|---|---|
| Price | $1,775.73 | $14.35 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $2,050.69 | N/A |
| AVG Volume (30 Days) | 194.1K | ★ 3.1M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 1.93% |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 26.54 | 0.14 |
| Revenue | $1,990,869,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $20.80 | $0.01 |
| Revenue Next Year | $16.38 | $0.49 |
| P/E Ratio | ★ $66.40 | $102.78 |
| Revenue Growth | ★ 15.91 | N/A |
| 52 Week Low | $1,300.00 | $12.80 |
| 52 Week High | $2,400.00 | $15.69 |
Technical Indicators
Market Signals| Indicator | FICO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 55.60 |
| Support Level | $1,756.00 | $14.28 |
| Resistance Level | $1,800.69 | $14.54 |
| Average True Range (ATR) | 50.86 | 0.14 |
| MACD | -3.17 | 0.03 |
| Stochastic Oscillator | 58.74 | 68.33 |
Price Performance
Historical ComparisonAbout FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.